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A B S T R A C T
Background: Somatic copy number alterations (SCNAs) occurring in tumors can provide information about
tumor classiﬁcation, patient's outcome or treatment targets. Liquid biopsies, incl. plasma samples containing
circulating cell-free tumor DNA (ccfDNA) can be used to assess SCNAs for clinical purposes, however specify and
reliability of methods have to be tested.
Methods: SNP microarrays (Aﬀymetrix) were used to generate whole-genome copy number proﬁles from plasma
ccfDNA (OncoScan) and paired tumor biopsies (CytoScan) from ten patients with metastatic cancers. Numerical,
segmental and focal SCNAs were assessed using ASCAT/TuScan and SNP-FASST2.
Results: Aberrations in ccfDNA in 4 patients resembled numerical (76%) and segmental (80%) aberrations in
tDNA. Three patients represented low correlation due to postponed sampling time, ccfDNA quality and possible
treatment interference. Breakpoints of high-amplitude ampliﬁcation were assessed with high accuracy and
relative breakpoints diﬀerence of only 7% (0.02–37%). Similarly, biallelic losses were reliably detected. Array
was 100% successful in detection of SCNAs on clinically relevant genes compared to SCNAs in tumor biopsies.
Tracking of SCNAs changes during the treatment course of one patient also indicated that apoptosis/necrosis of
non-cancerous cells presumably induced by treatment can inﬂuence ccfDNA composition and introduce false-
negative ﬁndings into the analysis of liquid biopsies.
Conclusions: Genomic alterations detected in ccfDNA from liquid biopsies by comprehensive SNP array are
reliable source for information for stratiﬁcation of patients for targeted treatment.
General signiﬁcance: Clinically relevant SCNAs can be detected in ccfDNA with high resolution and can therefore
serve as an alternative to tumor biopsy in deﬁning treatment targets.
1. Introduction
Molecular tumor proﬁling is essential for identiﬁcation of patients
that may be eligible for targeted therapy. Tumor tissue is normally
obtained from biopsies that not always reﬂect tumor heterogeneity.
Moreover, it may not be possible to obtain serial biopsies, restricting
the possibility to track tumor evolution and treatment response.
Therefore, liquid biopsies have emerged as an attractive alternative
for cancer diagnostics and their signiﬁcance dramatically increased
with the introduction of next-generation sequencing (NGS) into analysis
of circulating cell-free DNA (ccfDNA) released from the tumor.
The ccfDNA is released into the blood stream from necrotic and/or
apoptotic cells as longer size or shorter 160–180 bp fragments, respec-
tively [13]. The amount of ccfDNA is by itself a prognostic marker and
patients with increased levels of ccfDNA exhibit an unfavorable
prognosis [1,9]. PCR-based methods have been employed to identify
tumor-speciﬁc mutations and DNA methylation patterns during disease
progression and treatment (reviewed in [17]). Recently, advances in
next-generation sequencing (NGS) have enabled whole-genome/exome
sequencing (WGS, WES) of ccfDNA and depicted complex tumor
proﬁles from ccfDNA [4,14]. NGS has also been applied for detection
of particular somatic copy number alterations (SCNAs) [11,21] or
genome-wide SCNA proﬁles [19,26] in tumor samples, as well as, in
plasma [10]. Even though advances in bioinformatics in principle allow
for transformation of sequencing reads into quantitative assessment of
copy numbers, the derived SCNAs are sensitive to the quality of the
ccfDNA and the choice of processing algorithms and thresholds [10].
NGS based analyses have usually longer turn-around time and are still
relatively labor intensive and expensive for diagnostic purposes, i.e. if
individual samples have to be processed to meet patient report's
deadline and standards. Considering these limitations, array-based
approaches for detection of SCNAs in ccfDNA might have several
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beneﬁts in the clinical settings.
Arrays comprising a weighted distribution of SNPs on cancer
relevant genes were recently employed for SCNA analysis of ccfDNA
present in the urine from patients with urothelial bladder cancer [22].
The assay utilizes molecular inversion probe (MIP) technology [8] and
was initially designed for FFPE material. The technology is independent
of DNA fragment size, requires minimal DNA input and can partly
compensate for suboptimal DNA quality. In the present study, we
examined ccfDNA isolated from blood samples collected from patients
with various cancer types, and systematically compared whole-genome
copy number proﬁles obtained from ccfDNA with the corresponding
tumor biopsies. Speciﬁcally, we have focused on SCNAs occurring on
the genes with treatment relevance. We also show that the ccfDNA-
derived SCNA proﬁles can be used to monitor treatment response and
point out speciﬁc risks/challenges related to ccfDNA analysis.
2. Materials and methods
2.1. Patients and cfDNA samples
Patients (n = 10) provided written consent and all studies were
conducted in accordance with the Declaration of Helsinki. The clinical
data are summarized in Table 1. Brieﬂy, all patients had metastatic
disease with exhausted standard treatment options and were in physical
status allowing for their inclusion into various clinical trials. At the
inclusion, blood samples were collected in parallel with ultrasound-
guided tumor biopsies. All tumor specimens and peripheral blood draws
were collected as part of the ongoing Copenhagen Prospective Perso-
nalized Oncology (CoPPO) research project approved by the Danish
Ethical Committee [24]. Biopsies of seven patients were successfully
analyzed for SCNAs, whereas three patients were chosen due to the very
low aberrant cell fraction (< 5%) in biopsies, and where copy number
analysis was therefore not possible. Ten millilitres of peripheral blood
was collected in cell-free DNA BCT (Streck) tubes from each patient and
processed within 72 h. Plasma was prepared from the tubes using a
double spin procedure, including a ﬁrst spin at 2250 rcf at 4 °C for
20 min followed by a second centrifugation at 18,000 rcf at 4 °C for
20 min. Plasma was stored at−80 °C until further processing. Cell-free
DNA was extracted from 4 ml plasma using the QIAsymphony Circulat-
ing DNA Kit (Qiagen) according to manufacturer's protocol. DNA from
tumor biopsies was extracted using All prep DNA/RNA mini kit
(Qiagen). DNA quantiﬁcation was performed with the Qubit Fluorom-
eter (Invitrogen).
2.2. CytoScan and OncoScan assay
CytoScan assay (Aﬀymetrix, Santa Clara, USA) was performed on
fresh-frozen specimens from tumor biopsies according to the manufac-
tures instructions. Tumor samples were analyzed as a part of the
diagnostics in the CoPPO study where CytoScan is the pre-deﬁned
platform. OncoScan assay (Aﬀymetrix, Santa Clara, USA) for analysis of
ccfDNA was also performed according to the manufactures instructions.
The ccfDNA samples were analyzed retrospectively. To test the minimal
input of ccfDNA (recommended total DNA 80 ng), various amounts of
DNA with known SCNAs proﬁle were used as starting material. Brieﬂy,
25, 10, and 5 ng of tDNA with known SCNAs proﬁles were analyzed and
assessed by standard QC parameters. The results are summarized in Fig.
S1 and were used to estimate minimal input of ccfDNA used in the
study. SCNAs proﬁle of the testing sample was identical if using
CytoScan or OncoScan platform indicating that the applied platform
will have presumably minimal impact on the analysis.
2.3. Data analysis
OSCHP ﬁles from OncoScan and CEL ﬁles from the CytoScan assay
were imported into NEXUS software (BioDiscovery) and used for the
analysis and visualization of SCNAs and loss of heterozygosity (LOH).
Files are available at the GEO database under accession number
GSE85937. CytoScan CEL ﬁles were processes by ASCAT 2.1 (quadratic
correction, Gamma 0.55, removal of 3% outliers) and by pre-deﬁned
NEXUS settings (quadratic correction, median recenter probes, SNP-
FASST2 segmentation, removal of 3% outliers, and minimum of 50
probes per segment). OncoScan OSCHP ﬁles were processed similarly
by TuScan (Aﬀymetrix implementation of ASCAT) and by pre-deﬁned
NEXUS settings (ratio column as Log2Ratio, median recenter probes,
SNP-FASST2 segmentation, removal of 3% outliers, and minimum of 50
probes per segment). Overall, both approaches performed similarly on
OncoScan data (correlation in parameter “% of genome changed” was
R= 0.96), and had insigniﬁcant eﬀect on assessment of SCNAs of
interest. Both of the platforms require at least 10% tumor burden in
order to detect the somatic copy number aberrations. The SM Viewer
Software (Aﬀymetrix) was applied for detection of somatic mutations in
each sample. The platform requires at least 20–30% of mutation's
frequency in order to detect/assign its presence. Out of the 74 hot-spot
mutations detectable by the OncoScan (BRAF, KRAS, EGFR, IDH1,
IDH2, PTEN, PIK3CA, NRAS, TP53), one mutation (PIK3CA,
c.3140A > G, p.H1047R) was detected in Patient 8, what was in
concordance with the ﬁnding from whole-exome sequencing (routine in
CoPPO patients analysis; data not shown).
SCNAs (loss, gain, biallelic loss, or high ampliﬁcation) and LOH
calls for each sample were conﬁrmed by visual inspection and followed
by manual interpretation of whole-genome proﬁles. In general, pre-
sence of numerical (involving whole chromosome) and segmental
(involving at least two chromosomal bands) aberrations was assigned
for each chromosome. Subsequently, clinically relevant deletions/
biallelic losses and local ampliﬁcation (> 4 copies relative to average
ploidy on the particular chromosome) on 55 genes, selected based on
their treatment relevance [25], were examined.
Table 1
Patient cohort overview.
Patient # Diagnosis Age at
inclusion
Sex Biopsy site Days between cfDNA& tDNA
sampling
cfDNA concentration (ng/ml
plasma)
Days treatment-cfDNA
sampling
tDNA status
Patient 1 Stomach c. 65 M Liver 0 58.03 Known
Patient 2 Cholangiocarcinoma 34 M Liver 0 202.13 Known
Patient 3 Pancreas c. 58 F Liver 0 29.01 Known
Patient 4 Oesophagus c. 83 M Liver 0 191.13 Known
Patient 5 Lung c. 60 M Lymph node 96 10.63 Known
Patient 6 Colon c. 50 F Stomach 0 65.31 In treatment Known
Patient 7 Breast c. 60 F Skin 0 5.6 Known
Patient 8 Colon c. 74 F Liver 0 41.39 Unknown
Patient 9 Cervix c. 35 F Lymph node 0 8.31 Unknown
Patient 10 Colon c. 64 M Liver 0 27.23 Unknown
Age: Age at the inclusion to CoPPO study.
Days after last treatment: Days after the last treatment has been given.
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3. Results
3.1. Performance and limitations of ccfDNA analysis on arrays
In order to deﬁne the minimum input of ccfDNA (recommended
80 ng total DNA), diﬀerent total amounts of tDNA were used as a
starting material. Brieﬂy, 25, 10 and 5 ng of tDNA with known SCNAs
proﬁle was analyzed by OncoScan and assessed by standard QC
parameters as described above (Fig. S1). The lowest input (5 ng) failed
the most of the QC parameters, although displaying a visually
recognizable SCNAs proﬁle. 10 ng tDNA was border-line with respect
to the QC parameters as MAPD and WavinessSd, and showed a distinct
SCNA proﬁle, but algorithms failed to assign sample characteristics as
e.g. ploidy. The input of 25 ng passed all QC parameters and the sample
was correctly assessed for SCNAs, ploidy, and aberrant cell fraction. The
majority of the samples contained at least 20 ng of ccfDNA. Hence if
possible, a minimum input of 20 ng ccfDNA was used in the study. This
resulted in acceptable QC metrics in all but one sample.
Ten paired samples of ccfDNA and tDNA were subsequently
examined (Fig. 1A). Whereas, seven patients had known genomic
SCNAs proﬁles, the tumor proﬁle of three patients was unknown due
to the low aberrant cell fraction in tumor biopsies. The general
characteristics of the samples, i.e. ploidy, aberrant cell fraction and
percentage of genome changed generated by TuScan (cfDNA) and
ASCAT or SNP-FASST2 (tDNA), are listed in Table S1. Ploidy in ccfDNA
from the 7 patients only partially corresponded to the ploidy in tDNA.
Ploidy above 3.8 was assessed as diploid in ccfDNA, even though, visual
evaluation of logR ratios and BAF inclined towards the aneuploid
Fig. 1. Comparison of genomic proﬁles of ccfDNA and corresponding tDNA. (A) Overview plots showing probe densities on chromosomes for patient's paired samples. Upper plot for each
patient represents probe densities distribution in ccfDNA and below probe densities in tDNA. Numbers above the plot indicates chromosome numbers. (B) Boxplots for percentages of
genome subjected to aberrations in 7 patients with known genomic proﬁle as assigned in ccfDNA by TuScan, and in tDNA assigned by ASCAT and SNPFASST2. (C) Plot showing
percentual overlap of numerical (light-grey) and segmental (dark-grey) aberrations between tDNA and ccfDNA in individual patients. (D) Graph representing length of high amplitude
ampliﬁcations detected in ccfDNA (light-grey) and in corresponding tDNA (dark-grey). “P” on x-axis indicates patient's number and “c” chromosome. Error bars on ccfDNA columns
correspond to diﬀerences between individual break-points between tDNA and ccfDNA. (E) Chromosome view (NEXUS, BioDiscovery) on chromosome 9 in tDNA and ccfDNA. Arrows
mark biallelic deletion in 9p21.3 involving CDKN2A/B and is enlarged is section to the right. (F) Aberrations detected on clinically relevant cancer genes in tDNA and ccfDNA. Dark-blue
indicates alterations found in ccfDNA and tDNA. Light-grey marks alterations detected only in tDNA or only in ccfDNA. Light-blue marks corresponding alterations after performance of
manual correction.
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background (tetraploid) of tumor cells releasing the ccfDNA. Hence,
absence of correlation (Pearson; R =−0.06) between ploidy in
ccfDNA and tDNA more likely indicates possible limitations of TuScan
algorithm in estimating ploidy in ccfDNA.
When looking on the percentage of the genome subjected to SCNAs
(% of genome changed) as calculated by TuScan (ccfDNA) and by ASCAT
(tDNA), the similar trend was only seen in some sample pairs (Patient 1,
2, and 4). Overall, there was a tendency towards underestimation of
percentage of altered genome in ccfDNA by TuScan algorithm com-
pared to tDNA processed by ASCAT (Fig. 1B). This was reﬂected by the
low correlation between ccfDNA and tDNA (R = 0.58). Application of
SNP-FASST2 instead of ASCAT, improved the correlation between the
ccfDNA-tDNA pairs (R = 0.74), thus indicating need not only for an
algorithmic adjustment but also a possible biological phenomenon, as
e.g. presence of various tumor clones. Even though the above assessed
parameters are interesting in the large cohort studies, they will have
only minimal inﬂuence on the single patient diagnostics and for clinical
purposes, sensitivity in detection of particular SCNAs will be more
important.
3.2. Resolution in SCNAs detected in ccfDNA and in tumor biopsies
To assess the degree of correspondence between alterations detected
in ccfDNA and tumor biopsies, we investigated raw copy number
changes; i.e. whole chromosome gains or losses (numerical aberrations)
and subchromosomal gains and losses (segmental aberrations). The
percentage of identical aberrations in the seven patients with known
SCNAs proﬁle in tDNA was remarkably uneven (Fig. 1C). On average,
the analyzed patients had 53% (numerical aberrations) and 58%
(segmental aberrations) of identical events in ccfDNA and tDNA,
varying from 0 to 100%. Whereas aberrations in ccfDNA from patients
1–4 resembled to a high degree aberrations in tDNA (76% for numerical
and 80% for segmental aberrations, respectively), the three remaining
patients represented likeness only in 33% (Patient 5), 0% (Patient 6)
and 15% (Patient 7) of the events. Patient 5 was the only patient whose
biopsy was taken 95 days after the sampling of ccfDNA. Hence, the
observed discrepancy in the genomic proﬁles could reﬂect tumor
evolution. Indeed, tDNA was more altered than ccfDNA obtained
earlier, showing an overall shift in the ploidy (2.00 in ccfDNA and
4.63 in tDNA), as well as the presence of new segmental aberrations
(Fig. S3). Patient 7 had suboptimal ccfDNA input of 10 ng and failed
most of the array QC (Table S1). Patient 6 had ccfDNA showing
genomic proﬁle without SCNAs (Fig. S3). The diﬀerence to the other
patients was that Patient 6 received regorafenib treatment at the time of
ccfDNA sampling (issue investigated below), though hereby not ex-
cluding other possible causes. There was also marginal discrepancy
between detection of numerical and segmental aberrations in the
Patients 1–4 (Fig. 1C). While segmental aberrations were identical in
80% of events with standard deviation of 18.2%, numerical aberrations
displayed deviation of 34.5%. This was due to Patient 3, whose ccfDNA
had borderline QC parameters and contained substantial amount of
ccfDNA from normal cells; making the assessment of numerical aberra-
tions more challenging. Segmental aberrations, on the other hand, were
in general more pronounced and TuScan was able to detect diﬀerences
between segments with diﬀerent copy numbers.
In order to assess array resolution for detection of events in ccfDNA,
break-points of high amplitude focal ampliﬁcations and of biallelic
losses were analyzed. Ten high amplitude focal ampliﬁcations were
detected among the patients, and their size was deﬁned as a simple
diﬀerence (kb) between the break-points delineating the ampliﬁed
segment (Fig. 1D). Subsequently, diﬀerence between ccfDNA and tDNA
break-points position was calculated as percentual diﬀerence relative to
the size of ampliﬁed segment in tDNA. The average diﬀerence was
26.75% though including three distinct outliers. Exclusion of outliers
decreased the relative diﬀerence to 7%, ranging from 0.02% to 37.1%
indicating a high precision in array-based analysis of focal events in
ccfDNA. Furthermore, there was no correlation between segment length
and detected relative diﬀerence (R =−0.242). This suggests that
smaller or larger focal events are detected with equal resolution of
break-points and high accuracy. Interestingly in all cases, where
clinically relevant gene was detected as ampliﬁed in tDNA, the gene
was also ampliﬁed in ccfDNA (for examples see Fig. S2).
Detection of biallelic losses by DNA sequencing of ccfDNA remains
biased and particularly dependent on tumor content in the sample.
Noticeably, the three biallelic losses identiﬁed in our cohort were
detected in tDNA as well as in the ccfDNA counterparts; i.e. Patient 1:
15q22.2 (CCNB2), Patient 3: 9p21.3-p21.1 (CDKN2A/B), and Patient 4:
9p21.3 (CDKN2A/B) (Fig. 1E).
Taken together, the results show that array-based whole genome
analysis represents a suitable tool for SCNAs analysis of blood ccfDNA.
The genomic aberrations in tDNA are to a high degree reﬂected in
ccfDNA, however, the representative power of ccfDNA can be condi-
tioned by quality and quantity of ccfDNA as well as temporal and
biological factors.
3.3. Detection of clinically relevant SCNAs in ccfDNA
From a clinical point of view, numerical or segmental aberrations in
adult, non-CNS, solid tumors have rather prognostic than treatment
relevant impact. On contrary, ampliﬁcation (activation) or deletions/
LOH (loss-of-function) of a speciﬁc gene can represent a possible
treatment target. To verify the feasibility of ccfDNA for detection of
clinically relevant SCNAs, we analyzed 55 clinically relevant genes in
ccfDNA and in corresponding tumor biopsies. In the ﬁrst 4 patients with
comparable ccfDNA-tDNA pairs, a total number of 76 SCNAs were
detected in tumor biopsies. From those, 54 (70%) were also recognized
in ccfDNA (Fig. 1F). Discrepancies between the SCNAs calls were
caused either by missing LOH calls or by the over/under-estimation
of SCNA, i.e. gain interpreted as ampliﬁcation and vice versa, or
biallelic loss was assessed as monoallelic deletion. In all cases, the
diﬀerences could be explained by normal cell contamination and could
be corrected after visual inspection of genomic proﬁles (Fig. 1F). In
patients 8, 9, and 10, where the tumor biopsies only contained normal
cells, we identiﬁed 14 (Patient 8) and 9 (Patient 9) clinically relevant
SCNAs in ccfDNA (Fig. 1F). In Patient 10, ccfDNA did not possess
suﬃcient tumor burden. Hence, clinically relevant SCNAs can be
reliably detected in ccfDNA. The liquid biopsies can therefore be used
as an alternative source of SCNA information for deﬁning of treatment
targets where tumor biopsy is not an option.
3.4. Presumptive non-cancerous cell apoptosis can bias the diagnostic power
of ccfDNA
To further investigate the eﬀect of treatment on ccfDNA composi-
tion, we analyzed four ccfDNA samples collected during treatment of
Patient 5, and compared them to the genomic proﬁles of primary
tumor, and metastatic biopsies taken at inclusion and during the third
treatment protocol (Fig. 2A). The patient received targeted treatment
based on his mutation proﬁle (November 2014). Treatment was
changed in March 2015 and again in October 2015 with 5 days pause
between the treatment 2 and 3. The ccfDNA samples were collected
after initiation of treatments 1 and 2, between treatments 2 and 3 and
during treatment 3, 73 days after its initiation. Furthermore, an FFPE
sample from the primary lung tumor was available and analyzed by
OncoScan. Tumor biopsies were taken at the inclusion of the patient in
September 2014, i.e. before treatment 1 and three months after
initiation of treatment 3, in January 2016.
The diagnostic biopsy showed a relatively stable genomic proﬁle
characterized by unbalanced gain of 8q and LOH on chromosome 13. At
CoPPO inclusion, metastatic tDNA was more aﬀected and displayed
aneuploidy on several chromosomes, pronounced ampliﬁcation 8q,
LOH on chromosome 13, and in addition, unbalanced gain/ampliﬁca-
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tion of 11q, local gain 12q13 and 17p deletion. After the third
treatment regime, tDNA showed less prominent aberrations, as simple
gain 8q and LOH on chromosome 13, and lacked 17p deletion or high
gain 11q observed in the pre-treatment biopsy (Fig. 2A,B). Interest-
ingly, despite having comparable plasma concentrations of ccfDNA (31,
14, 11 and 20 ng/ml, respectively), none of the ccfDNA samples, taken
under the treatments, contained suﬃcient amount of tumor ccfDNA.
None of the aberrations observed in tDNA could be detected in ccfDNA.
The only ccfDNA sample with recognizable SCNAs was obtained
between treatments, i.e. between treatment 2 and 3. The SCNAs
resembled to a large extend SCNAs from pre- and in-treatment biopsies;
e.g. high gain 8q, deletion 17p, LOH on chromosome 13 and gain 11q.
These results indicate that apoptosis/necrosis of non-cancerous cells
induced by chemotherapy can inﬂuence ccfDNA composition and
introduce false-negative ﬁndings into the whole-genome SCNAs analy-
sis of liquid biopsies. Indeed, used array platform and subsequent data
processing require at least 10–30% of tumor burden in order to detect
the deviations from normal cell proﬁle. Moreover, OncoScan detects
mutations with frequency of at least 20–30%. In agreement with these
observations, patients BRAF driver mutation, was detected in ccfDNA
by ddPCR with frequency of app. 1% for in-treatment samples and of
10.8% in between-treatment sample (unpublished results), hence far
below the array sensitivity. However, we cannot exclude other techni-
cal factors aﬀecting DNA composition [23], nor the tumor behavior
acquiring more quiescent state during the treatment.
4. Discussion
SCNAs including oncogenes or tumor suppressor genes can be
deeply involved in tumor progression. For clinical purposes, a number
of the ampliﬁed genes may be targeted by speciﬁc drugs such as ERBB2
([18] orMET [15]. The alteration in genomic proﬁle can also pint-point
the tumors with defects in homologous recombination and hereby
deﬁne patients sensitive to PARP inhibitors [12]. Consequently, fast
and reliable SCNAs analysis is becoming an important part of the
clinical cancer diagnostics. In parallel, molecular proﬁling of cancer
biomarkers circulating in the blood is an emerging companion diag-
nostic. However, clinical implementation is still precautious and limited
by the lack of knowledge about the origin and function of ccfDNA [7],
one-angle molecular characterization [17] and absence of analytical
Fig. 2. Patient case. (A) Longitudinal study of genomic aberrations in tDNA and ccfDNA obtained from Patient 5 before and during treatment. The top part of the ﬁgure shows whole
genome proﬁles of tDNA, analyzed by CytoScan, originating from diagnostic (blue rectangle), pre- (green rectangle) and in-treatment (red rectangle) biopsies. Below are whole genome
proﬁles of ccfDNA analyzed by OncoScan, and sampled after the initiation of treatment 1 and 2 (blue empty rectangle), between treatments 2 and 3 (green empty rectangle) and after
73 days of treatment 3 (red empty rectangle). Notice the absence of aberrations in cfDNA obtained under treatment. (B) Distribution of numerical and segmental aberrations and of focal
alterations in cancer related genes in diagnostic, pre-treatment and in-treatment biopsies and chronologically placed ccfDNA obtained between treatments 2 and 3. (For interpretation of
the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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consensus [3]. In this study, we have validated an array-based copy
number analysis of plasma ccfDNA from metastatic cancer patients
eligible for inclusion into clinical trials, and hereby supplied a reliable
tool required for complex molecular proﬁling of ccfDNA.
Systematic comparison of ccfDNA and tDNA obtained from tumor
biopsy showed that genomic SCNAs proﬁle assembled from ccfDNA to a
high degree reﬂects SCNAs in a tumor. Though, the representative
power of ccfDNA can be temporally conditioned, as illustrated by the
case where tumor DNA was obtained> 2 months after the ccfDNA
sample. In some occasions, genomic proﬁles of ccfDNA can also
marginally diﬀer from those of tDNA obtained from simultaneous
biopsies. In view of that, the overlap of numerical and segmental
aberrations was never 100%. Considering that a biopsy represents only
a temporal and spatial snap-shot of a tumor, there is a risk for misled
discovery of potential targets. Hence, ccfDNA can be more representa-
tive of the tumor burden than a single biopsy [11]. Therefore, complex
analysis of ccfDNA including sequencing and SCNAs proﬁling can
contribute to exploration of tumor heterogeneity [2,5], major clone
characterization and disclose the presence of other lesions.
It was noteworthy that treatment was also found to have a profound
eﬀect on the ccfDNA composition. This phenomenon was previously
reported as an accidental ﬁnding in a lung cancer patient who received
neoadjuvant treatment during ccfDNA sampling [26]. Here, the ﬁnding
was hypothetically explained by rapid tumor shrinkage leading to de-
attachment of tumor from adjacent blood supply, and thus to limited
release of ccfDNA into the blood stream. However, ccfDNA in our study
was taken not only 1–2 days after the treatment initiation but also more
than a month in a treatment. The possible explanation can be then
based on the fact that the majority of ccfDNA is of non-cancerous origin
and originates from apoptotic and stressed cells [6]. Chemotherapy and
radiotherapy can stress normal cells and increase non-cancerous
ccfDNA release. The SCNAs proﬁle of tumor ccfDNA is then diluted
by normal cell ccfDNA and alters the results of ccfDNA analysis. This
was clearly manifested on the case study where all ccfDNA samples
taken under the treatments showed genomic proﬁles without detectable
SCNAs. Hereby, we raise the consideration that apoptosis/necrosis of
normal cells induced by chemotherapy/targeted therapy can inﬂuence
ccfDNA composition and therefore introduce false-negative ﬁndings in
the SCNAs analysis of liquid biopsies. OncoScan can only detect SCNAs
if the tumor burden is above min.10%.
Sensitivity of OncoScan to detect SCNAs is one of the strongest
limitations of this technique (Table 2). Requirement for particular
amount (optimal input of 20 ng) and composition of ccfDNA (optimal
above 30% of tumor DNA burden) is strongly limiting its application.
Especially early stage patients with low tumor mass, patients with
ongoing treatment and/or patient with CNS tumors might not be
eligible for diagnostics by OncoScan. On the other hand, proﬁle without
SCNAs might on its own be an indication of response. Relevant cohort
studies however need to verify this hypothesis.
The sensitivity issue of the arrays and related algorithms can be on
the other hand compensated by NGS techniques (detection of mutations
with 0.5–1% frequency) or by specialized methods such as ddPCR,
which can detect mutations with frequency of 0.005% [16]. However,
reliable estimation of tumor burden cannot be detected by low-cover-
age NGS technology (< 50×) and requires reliable SCNA analytical
platform as the one demonstrated here. On the other hand, advances in
bioinformatics (e.g. ABSOLUTE) will probably soon overcome this
obstacle and allow for estimation of high amplitude ampliﬁcation also
in diagnostic settings. Nevertheless, techniques allowing for the assess-
ment of aberrant cell fractions appear to be an essential supplement for
proper interpretation of ccfDNA analysis results.
Even though numerical and segmental aberrations can vary between
tDNA and ccfDNA as described above, driver events including local
ampliﬁcations or deletions/biallelic losses remain consistent during
tumor evolution [20]. The analysis of 55 genes conﬁrmed this view,
since every SCNA detected in tDNA was also present in ccfDNA. SCNAs
detected in ccfDNA can therefore be directly used for patient stratiﬁca-
tion. Yet, the majority of SCNAs on clinically relevant genes is only
indicative for treatment and requires further assessment of e.g. muta-
tions in the particular gene. Deletions/LOHs are a typical examples
when in order to achieve biallelic inactivation and fulﬁll the criteria for
targeted treatment; the remaining allele has to contain an inactivating
mutation. Targeted DNA sequencing [21] or massively multiplexed PCR
[11] of ccfDNA still meet the diﬃculties of estimation of deletions/
biallelic losses. Therefore, a supplement of array-based SCNAs analysis
to targeted DNA sequencing/WES for genomic screening of cancer
patients appears to be an optimal solution for ccfDNA analysis in
diagnostic settings.
5. Conclusion
Our results validate a new method for precise detection of copy
number alterations in ccfDNA isolated from liquid biopsies (blood) with
a great potential to be implemented in the cancer diagnostics within a
short time. The genomic aberrations detected in ccfDNA resemble to a
high degree alterations in corresponding tumor biopsies. Moreover,
array-based genomic proﬁling provides high resolution and precision in
detection of clinically relevant alterations. For proper interpretation of
ccfDNA proﬁles, it is however essential to consider certain technical
and biological pitfalls (Table 2). The major concern raised by our study
is treatment, which can signiﬁcantly alter ccfDNA composition by
increasing the release of ccfDNA from non-cancerous cells.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbacli.2017.03.006.
Table 2
Overview over advantages and disadvantages in use of OncoScan for genome-wide analysis of SCNAs in circulating cell-free tumor DNA.
Characteristics Comments Contras
Input material 20 ng ccfDNA 5 ng is possible for recognizable SCNAs proﬁle Patient with low tumor mass excluded
Processing algorithm TuScan Freely available via NEXUS (BioDiscovery)
Ploidy assessment Yes Manual correction required
Estimation of altered genome Yes Only informative, not for diagnostic purposes
Aberrant cell fraction Yes Best performance with> 50% of aberrant cell
fraction
Composition of ccfDNA might cause false-negative ﬁndings
Resolution and sensitivity of SCNAs detection
SCNAs Precision
Numerical SCNAs 20–100% Visual inspection and correction required Information about possible biological bias is required; e.g. treatment,
heterogeneity, time of samplingSegmental SCNAs 40–100% Visual inspection and correction required
High amplitude ampliﬁcation 100% Deviation in assignment of break-points is 7% of
segment length
Biallelic losses Yes
Clinically relevant aberration 70(100)% Precision is 100% after manual correction of LOH Need for manual interference
O. Østrup et al. BBA Clinical 7 (2017) 120–126
125
Acknowledgments
Maria Guschina, Julie Fisker Nielsen and Susanne Smed are thanked
for their excellent technical assistance.
References
[1] C. Bettegowda, M. Sausen, R.J. Leary, I. Kinde, Y. Wang, N. Agrawal, B.R. Bartlett,
H. Wang, B. Luber, R.M. Alani, E.S. Antonarakis, N.S. Azad, A. Bardelli, H. Brem,
J.L. Cameron, C.C. Lee, L.A. Fecher, G.L. Gallia, P. Gibbs, D. Le, R.L. Giuntoli,
M. Goggins, M.D. Hogarty, M. Holdhoﬀ, S.M. Hong, Y. Jiao, H.H. Juhl, J.J. Kim,
G. Siravegna, D.A. Laheru, C. Lauricella, M. Lim, E.J. Lipson, S.K. Marie, G.J. Netto,
K.S. Oliner, A. Olivi, L. Olsson, G.J. Riggins, A. Sartore-Bianchi, K. Schmidt,
I.M. Shih, S.M. Oba-Shinjo, S. Siena, D. Theodorescu, J. Tie, T.T. Harkins,
S. Veronese, T.L. Wang, J.D. Weingart, C.L. Wolfgang, L.D. Wood, D. Xing,
R.H. Hruban, J. Wu, P.J. Allen, C.M. Schmidt, M.A. Choti, V.E. Velculescu,
K.W. Kinzler, B. Vogelstein, N. Papadopoulos, L.A. Diaz Jr., Detection of circulating
tumor DNA in early- and late-stage human malignancies, Sci. Transl. Med. 6 (2014)
224ra224.
[2] N. Bolli, H. Avet-Loiseau, D.C. Wedge, P. Van Loo, L.B. Alexandrov, I. Martincorena,
K.J. Dawson, F. Iorio, S. Nik-Zainal, G.R. Bignell, J.W. Hinton, Y. Li, J.M. Tubio,
S. McLaren, O.M. S, A.P. Butler, J.W. Teague, L. Mudie, E. Anderson, N. Rashid,
Y.T. Tai, M.A. Shammas, A.S. Sperling, M. Fulciniti, P.G. Richardson, G. Parmigiani,
F. Magrangeas, S. Minvielle, P. Moreau, M. Attal, T. Facon, P.A. Futreal,
K.C. Anderson, P.J. Campbell, N.C. Munshi, Heterogeneity of genomic evolution
and mutational proﬁles in multiple myeloma, Nat. Commun. 5 (2014) 2997.
[3] A.J. Bronkhorst, J. Aucamp, P.J. Pretorius, Cell-free DNA: preanalytical variables,
Clin. Chim. Acta 450 (2015) 243–253.
[4] K.C. Chan, P. Jiang, Y.W. Zheng, G.J. Liao, H. Sun, J. Wong, S.S. Siu, W.C. Chan,
S.L. Chan, A.T. Chan, P.B. Lai, R.W. Chiu, Y.M. Lo, Cancer genome scanning in
plasma: detection of tumor-associated copy number aberrations, single-nucleotide
variants, and tumoral heterogeneity by massively parallel sequencing, Clin. Chem.
59 (2013) 211–224.
[5] M. Chicard, S. Boyault, L. Colmet Daage, W. Richer, D. Gentien, G. Pierron,
E. Lapouble, A. Bellini, N. Clement, I. Iacono, S. Brejon, M. Carrere, C. Reyes,
T. Hocking, V. Bernard, M. Peuchmaur, N. Corradini, C. Faure-Conter, C. Coze,
D. Plantaz, A.S. Defachelles, E. Thebaud, M. Gambart, F. Millot, D. Valteau-
Couanet, J. Michon, A. Puisieux, O. Delattre, V. Combaret, G. Schleiermacher,
Genomic copy number proﬁling using circulating free tumor DNA highlights
heterogeneity in neuroblastoma, Clin. Cancer Res. 22 (2016) 5564–5573.
[6] K. Glebova, N. Veiko, S. Kostyuk, V. Izhevskaya, A. Baranova, Oxidized extra-
cellular DNA as a stress signal that may modify response to anticancer therapy,
Cancer Lett. 356 (2015) 22–33.
[7] S. Gravina, J.M. Sedivy, J. Vijg, The dark side of circulating nucleic acids, Aging
Cell 15 (2016) 398–399.
[8] P. Hardenbol, J. Baner, M. Jain, M. Nilsson, E.A. Namsaraev, G.A. Karlin-Neumann,
H. Fakhrai-Rad, M. Ronaghi, T.D. Willis, U. Landegren, R.W. Davis, Multiplexed
genotyping with sequence-tagged molecular inversion probes, Nat. Biotechnol. 21
(2003) 673–678.
[9] D. Hashad, A. Sorour, A. Ghazal, I. Talaat, Free circulating tumor DNA as a
diagnostic marker for breast cancer, J. Clin. Lab. Anal. 26 (2012) 467–472.
[10] E. Heitzer, M. Auer, P. Ulz, J.B. Geigl, M.R. Speicher, Circulating tumor cells and
DNA as liquid biopsies, Genome Med. 5 (2013) 73.
[11] E. Kirkizlar, B. Zimmermann, T. Constantin, R. Swenerton, B. Hoang, N. Wayham,
J.E. Babiarz, Z. Demko, R.J. Pelham, S. Kareht, A.L. Simon, K.N. Jinnett,
M. Rabinowitz, S. Sigurjonsson, M. Hill, Detection of clonal and subclonal copy-
number variants in cell-free DNA from patients with breast cancer using a massively
multiplexed PCR methodology, Transl. Oncol. 8 (2015) 407–416.
[12] J. Mateo, S. Carreira, S. Sandhu, S. Miranda, H. Mossop, R. Perez-Lopez, D. Nava
Rodrigues, D. Robinson, A. Omlin, N. Tunariu, G. Boysen, N. Porta, P. Flohr,
A. Gillman, I. Figueiredo, C. Paulding, G. Seed, S. Jain, C. Ralph, A. Protheroe,
S. Hussain, R. Jones, T. Elliott, U. McGovern, D. Bianchini, J. Goodall, Z. Zafeiriou,
C.T. Williamson, R. Ferraldeschi, R. Riisnaes, B. Ebbs, G. Fowler, D. Roda, W. Yuan,
Y.M. Wu, X. Cao, R. Brough, H. Pemberton, R. A'Hern, A. Swain, L.P. Kunju,
R. Eeles, G. Attard, C.J. Lord, A. Ashworth, M.A. Rubin, K.E. Knudsen, F.Y. Feng,
A.M. Chinnaiyan, E. Hall, J.S. de Bono, DNA-repair defects and olaparib in
metastatic prostate cancer, N. Engl. J. Med. 373 (2015) 1697–1708.
[13] F. Mouliere, B. Robert, E. Arnau Peyrotte, M. Del Rio, M. Ychou, F. Molina,
C. Gongora, A.R. Thierry, High fragmentation characterizes tumour-derived
circulating DNA, PLoS One 6 (2011) e23418.
[14] M. Murtaza, S.J. Dawson, D.W. Tsui, D. Gale, T. Forshew, A.M. Piskorz,
C. Parkinson, S.F. Chin, Z. Kingsbury, A.S. Wong, F. Marass, S. Humphray,
J. Hadﬁeld, D. Bentley, T.M. Chin, J.D. Brenton, C. Caldas, N. Rosenfeld, Non-
invasive analysis of acquired resistance to cancer therapy by sequencing of plasma
DNA, Nature 497 (2013) 108–112.
[15] M. Nishio, A. Horiike, H. Nokihara, H. Horinouchi, S. Nakamichi, H. Wakui,
F. Ohyanagi, K. Kudo, N. Yanagitani, S. Takahashi, Y. Kuboki, N. Yamamoto,
Y. Yamada, M. Abe, T. Tahata, T. Tamura, Phase I study of the anti-MET antibody
onartuzumab in patients with solid tumors and MET-positive lung cancer, Investig.
New Drugs 33 (2015) 632–640.
[16] K. Page, D.S. Guttery, D. Fernandez-Garcia, A. Hills, R.K. Hastings, J. Luo,
K. Goddard, V. Shahin, L. Woodley-Barker, B.M. Rosales, R.C. Coombes, J. Stebbing,
J.A. Shaw, Next generation sequencing of circulating cell-free DNA for evaluating
mutations and gene ampliﬁcation in metastatic breast cancer, Clin. Chem. 63
(2017) 532–541.
[17] J. Polivka Jr., M. Pesta, F. Janku, Testing for oncogenic molecular aberrations in
cell-free DNA-based liquid biopsies in the clinic: are we there yet? Expert. Rev. Mol.
Diagn. 15 (2015) 1631–1644.
[18] K.I. Pritchard, L.E. Shepherd, F.P. O'Malley, I.L. Andrulis, D. Tu, V.H. Bramwell,
M.N. Levine, National Cancer Institute of Canada Clinical Trials, G, HER2 and
responsiveness of breast cancer to adjuvant chemotherapy, N. Engl. J. Med. 354
(2006) 2103–2111.
[19] D.G. Rothwell, N. Smith, D. Morris, H.S. Leong, Y. Li, A. Hollebecque, M. Ayub,
L. Carter, J. Antonello, L. Franklin, C. Miller, F. Blackhall, C. Dive, G. Brady, Genetic
proﬁling of tumours using both circulating free DNA and circulating tumour cells
isolated from the same preserved whole blood sample, Mol. Oncol. 10 (2016)
566–574.
[20] A. Sottoriva, H. Kang, Z. Ma, T.A. Graham, M.P. Salomon, J. Zhao, P. Marjoram,
K. Siegmund, M.F. Press, D. Shibata, C. Curtis, A Big Bang model of human
colorectal tumor growth, Nat. Genet. 47 (2015) 209–216.
[21] E. Takai, Y. Totoki, H. Nakamura, C. Morizane, S. Nara, N. Hama, M. Suzuki,
E. Furukawa, M. Kato, H. Hayashi, T. Kohno, H. Ueno, K. Shimada, T. Okusaka,
H. Nakagama, T. Shibata, S. Yachida, Clinical utility of circulating tumor DNA for
molecular assessment in pancreatic cancer, Sci. Rep. 5 (2015) 18425.
[22] F.S. Togneri, D.G. Ward, J.M. Foster, A.J. Devall, P. Wojtowicz, S. Alyas,
F.R. Vasques, A. Oumie, N.D. James, K.K. Cheng, M.P. Zeegers, N. Deshmukh,
B. O'Sullivan, P. Taniere, K.G. Spink, D.J. McMullan, M. Griﬃths, R.T. Bryan,
Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA, Eur. J.
Hum. Genet. 24 (2016) 1167–1174.
[23] P.V. Toro, B. Erlanger, J.A. Beaver, R.L. Cochran, D.A. VanDenBerg, E. Yakim,
K. Cravero, D. Chu, D.J. Zabransky, H.Y. Wong, S. Croessmann, H. Parsons,
P.J. Hurley, J. Lauring, B.H. Park, Comparison of cell stabilizing blood collection
tubes for circulating plasma tumor DNA, Clin. Biochem. 48 (2015) 993–998.
[24] I.V. Tuxen, L. Jonson, E. Santoni-Rugiu, J.P. Hasselby, F.C. Nielsen, U. Lassen,
Personalized oncology: genomic screening in phase 1, APMIS 122 (2014) 723–733.
[25] E.M. Van Allen, N. Wagle, P. Stojanov, D.L. Perrin, K. Cibulskis, S. Marlow, J. Jane-
Valbuena, D.C. Friedrich, G. Kryukov, S.L. Carter, A. McKenna, A. Sivachenko,
M. Rosenberg, A. Kiezun, D. Voet, M. Lawrence, L.T. Lichtenstein, J.G. Gentry,
F.W. Huang, J. Fostel, D. Farlow, D. Barbie, L. Gandhi, E.S. Lander, S.W. Gray,
S. Joﬀe, P. Janne, J. Garber, L. MacConaill, N. Lindeman, B. Rollins, P. Kantoﬀ,
S.A. Fisher, S. Gabriel, G. Getz, L.A. Garraway, Whole-exome sequencing and
clinical interpretation of formalin-ﬁxed, paraﬃn-embedded tumor samples to guide
precision cancer medicine, Nat. Med. 20 (2014) 682–688.
[26] S. Xia, C.C. Huang, M. Le, R. Dittmar, M. Du, T. Yuan, Y. Guo, Y. Wang, X. Wang,
S. Tsai, S. Suster, A.C. Mackinnon, L. Wang, Genomic variations in plasma cell free
DNA diﬀerentiate early stage lung cancers from normal controls, Lung Cancer 90
(2015) 78–84.
O. Østrup et al. BBA Clinical 7 (2017) 120–126
126
